GSK’s Shingrix On Recovery Track In Q3 After Pandemic Slump
Newer Drugs Fuel HIV Sales Growth
The shingles vaccine’s move to health care practices, as well as inventory moves, contributed to its 41% sales growth during the quarter after a difficult year due to COVID-19.
